Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Enteroaggregative Escherichia coli heat-stable enterotoxin 1 (EAST1) is a 38-amino acid secretory peptide toxin produced primarily by enteroaggregative E. coli (EAEC) and other diarrheagenic strains, including enterotoxigenic (ETEC) and enterohemorrhagic E. coli (EHEC) (PMID: 8603943). Encoded by the astA gene, EAST1 is a member of the heat-stable enterotoxin family and shares significant structural and functional homology with the E. coli STa enterotoxin and the endogenous mammalian peptides guanylin and uroguanylin (PMID: 8385356, 12003040). It functions by binding to and activating the membrane-bound guanylate cyclase C (GC-C) receptor on the apical surface of intestinal epithelial cells. This activation leads to a rapid increase in intracellular cyclic guanosine monophosphate (cGMP), which subsequently triggers chloride secretion through the cystic fibrosis transmembrane conductance regulator (CFTR) and inhibits sodium absorption via the NHE3 exchanger (PMID: 35712128). The resulting accumulation of electrolytes and water in the intestinal lumen causes the watery diarrhea characteristic of EAEC and ETEC infections (PMID: 12003040). While its specific role in disease severity is sometimes debated, EAST1 is recognized as a key virulence factor in traveler's diarrhea and persistent childhood diarrhea, making it a target for diagnostic identification and the development of neutralizing anti-toxin therapies or multivalent vaccines (PMID: 35712128, 22897534).
Activation of the host intestinal receptor guanylate cyclase C (GC-C), which increases intracellular cGMP levels to stimulate CFTR-mediated chloride secretion and inhibit sodium absorption (PMID: 8385356, 12003040).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Enteroaggregative Escherichia coli heat-stable enterotoxin 1 (EAST1).